Publications

Add filters (0)

9 results

Osteoarthritis phenotypes and novel therapeutic targets.

July 1, 2019

Biochem Pharmacol

Abstract The success of disease-modifying osteoarthritis drug (DMOAD) development is still elusive. While there have been successes in preclinical and early clinical studies, phase 3 clinical trials have failed so far and there is still no approved, widely available DMOAD on the market. The latest research suggests that, among other causes, poor trial outcomes might […]

Read publication

Zoledronate prevents lactation induced bone loss and results in additional post-lactation bone mass in mice.

June 1, 2016

Bone

Abstract In rodents, lactation is associated with a considerable and very rapid bone loss, which almost completely recovers after weaning. The aim of the present study was to investigate whether the bisphosphonate Zoledronate (Zln) can inhibit lactation induced bone loss, and if Zln interferes with recovery of bone mass after lactation has ceased. Seventy-six 10-weeks-old […]

Read publication

The development and characterization of an ELISA specifically detecting the active form of cathepsin K.

October 1, 2013

Clin Biochem

Abstract OBJECTIVE Cathepsin K plays essential roles in bone resorption and is intensely investigated as a therapeutic target for the treatment of osteoporosis. Hence an assessment of the active form of cathepsin K may provide important biological information in metabolic bone diseases, such as osteoporosis or ankylosing spondylitis. METHODS Presently there are no robust assays […]

Read publication

Enzyme-linked immunosorbent serum assays (ELISAs) for rat and human N-terminal pro-peptide of collagen type I (PINP)–assessment of corresponding epitopes.

October 1, 2010

Clin Biochem

Abstract OBJECTIVES The present study describes two newly developed N-terminal pro-peptides of collagen type I (PINP) competitive enzyme-linked immunosorbent assays (ELISAs) for the assessment of corresponding PINP epitopes in the rat- and human species. METHODS Monoclonal antibodies were raised against corresponding rat and human PINP sequences and competitive assays were developed for each species. They […]

Read publication

Alterations in osteoclast function and phenotype induced by different inhibitors of bone resorption–implications for osteoclast quality.

June 1, 2010

BMC Musculoskelet Disord

Abstract BACKGROUND Normal osteoclasts resorb bone by secretion of acid and proteases. Recent studies of patients with loss of function mutations affecting either of these processes have indicated a divergence in osteoclastic phenotypes. These difference in osteoclast phenotypes may directly or indirectly have secondary effects on bone remodeling, a process which is of importance for […]

Read publication

The disease modifying osteoarthritis drug (DMOAD): Is it in the horizon?

July 1, 2008

Pharmacol Res

Abstract Till date, the pharmaceutical industry has failed to bring effective and safe disease modifying osteoarthritic drugs (DMOADs) to the millions of patients suffering from this serious and deliberating disease. We provide a review of recent data reported on the investigation of DMOADs in clinical trials, including compounds inhibiting matrix-metalloproteinases (MMPs), bisphosphonates, cytokine blockers, calcitonin, […]

Read publication

Bone turnover and bone collagen maturation in osteoporosis: effects of antiresorptive therapies.

March 1, 2008

Osteoporos Int

Abstract UNLABELLED Bone collagen maturation may be important for anti-fracture efficacy as the reduction in risk is only partly explained by a concomitant increase in BMD during anti-resorptive therapy. Different treatments caused diverse profiles in bone collagen degradation products, which may have implications for bone quality. INTRODUCTION The aim of the present study was to […]

Read publication

Measurement of tumor load and distribution in a model of cancer-induced osteolysis: a necessary precaution when testing novel anti-resorptive therapies.

January 1, 2004

Clin Exp Metastasis

Abstract The Arguello model of cancer metastasis to bone has been used extensively to study breast cancer-induced osteolytic disease. The effects of therapy on skeletal disease and on tumour burden in soft organs are traditionally measured using radiography and/or time-consuming histomorphometry, respectively. The purpose of this study was to develop a sensitive and efficient method […]

Read publication

Investigation of bone disease using isomerized and racemized fragments of type I collagen.

January 1, 2003

Calcif Tissue Int

Abstract In the collagen type I C-telopeptide an aspartyl-glycine site within the sequence AHDGGR is susceptible to molecular rearrangement. In newly synthesized collagen this site is in the native form, denoted alpha L. During aging a spontaneous reaction occurs resulting in three age-modified forms: an isomerized form (beta L) a racemized form (alpha D), and […]

Read publication